These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 36468954)

  • 41. Adalimumab (antitumour necrosis factor-α) treatment of hidradenitis suppurativa ameliorates skin inflammation: an in situ and ex vivo study.
    van der Zee HH; Laman JD; de Ruiter L; Dik WA; Prens EP
    Br J Dermatol; 2012 Feb; 166(2):298-305. PubMed ID: 22013960
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Keratinocytes and immune cells in the epidermis are key drivers of inflammation in hidradenitis suppurativa providing a rationale for novel topical therapies.
    Schell SL; Cong Z; Sennett ML; Gettle SL; Longenecker AL; Goldberg SR; Kirby JS; Helm MF; Nelson AM
    Br J Dermatol; 2023 Feb; 188(3):407-419. PubMed ID: 36680309
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Biologic therapies for the treatment of hidradenitis suppurativa.
    Rosales Santillan M; Morss PC; Porter ML; Kimball AB
    Expert Opin Biol Ther; 2020 Jun; 20(6):621-633. PubMed ID: 32077334
    [No Abstract]   [Full Text] [Related]  

  • 44. The role of interleukin-17 in the pathogenesis of hidradenitis suppurativa.
    Yao Y; Thomsen SF
    Dermatol Online J; 2017 Jul; 23(7):. PubMed ID: 29469692
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Metformin as Adjunctive Therapy for Pediatric Patients With Hidradenitis Suppurativa.
    Moussa C; Wadowski L; Price H; Mirea L; O'Haver J
    J Drugs Dermatol; 2020 Dec; 19(12):1231-1234. PubMed ID: 33346525
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dapsone to Treat Moderate-to-Severe Hidradenitis Suppurativa: A Retrospective Case-Series.
    Baroudi B; Bashyam AM; Feldman SR; Pichardo RO
    J Drugs Dermatol; 2023 Nov; 22(11):e12-e16. PubMed ID: 37943259
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical Implementation of Biologics and Small Molecules in the Treatment of Hidradenitis Suppurativa.
    Aarts P; Dudink K; Vossen ARJV; van Straalen KR; Ardon CB; Prens EP; van der Zee HH
    Drugs; 2021 Aug; 81(12):1397-1410. PubMed ID: 34283386
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Biologic Treatment for Hidradenitis Suppurativa.
    Flood KS; Porter ML; Kimball AB
    Am J Clin Dermatol; 2019 Oct; 20(5):625-638. PubMed ID: 31140067
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The Clinical Significance of Increased Serum Proinflammatory Cytokines, C-Reactive Protein, and Erythrocyte Sedimentation Rate in Patients with Hidradenitis Suppurativa.
    Jiménez-Gallo D; de la Varga-Martínez R; Ossorio-García L; Albarrán-Planelles C; Rodríguez C; Linares-Barrios M
    Mediators Inflamm; 2017; 2017():2450401. PubMed ID: 28769536
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Emerging drugs for the treatment of hidradenitis suppurativa.
    Folkes AS; Hawatmeh FZ; Wong A; Kerdel FA
    Expert Opin Emerg Drugs; 2020 Sep; 25(3):201-211. PubMed ID: 32667213
    [TBL] [Abstract][Full Text] [Related]  

  • 51. An open-label study of anakinra for the treatment of moderate to severe hidradenitis suppurativa.
    Leslie KS; Tripathi SV; Nguyen TV; Pauli M; Rosenblum MD
    J Am Acad Dermatol; 2014 Feb; 70(2):243-51. PubMed ID: 24314876
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Increased interleukin (IL)-17 serum levels in patients with hidradenitis suppurativa: Implications for treatment with anti-IL-17 agents.
    Matusiak Ł; Szczęch J; Bieniek A; Nowicka-Suszko D; Szepietowski JC
    J Am Acad Dermatol; 2017 Apr; 76(4):670-675. PubMed ID: 28041632
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Biologics for Hidradenitis suppurativa: evolution of the treatment paradigm.
    Maronese CA; Moltrasio C; Genovese G; Marzano AV
    Expert Rev Clin Immunol; 2024 May; 20(5):525-545. PubMed ID: 38130204
    [TBL] [Abstract][Full Text] [Related]  

  • 54. IL-17 Inhibition: A Valid Therapeutic Strategy in the Management of Hidradenitis Suppurativa.
    Malvaso D; Calabrese L; Chiricozzi A; Antonelli F; Coscarella G; Rubegni P; Peris K
    Pharmaceutics; 2023 Oct; 15(10):. PubMed ID: 37896210
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Paradoxical Hidradenitis Suppurativa in Patients Receiving TNF-α Inhibitors: Case Series, Systematic Review, and Case Meta-Analysis.
    Salvador-Rodriguez L; Montero-Vílchez T; Arias-Santiago S; Molina-Leyva A
    Dermatology; 2020; 236(4):307-313. PubMed ID: 32135533
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Safety and Efficacy of Anakinra in Severe Hidradenitis Suppurativa: A Randomized Clinical Trial.
    Tzanetakou V; Kanni T; Giatrakou S; Katoulis A; Papadavid E; Netea MG; Dinarello CA; van der Meer JWM; Rigopoulos D; Giamarellos-Bourboulis EJ
    JAMA Dermatol; 2016 Jan; 152(1):52-59. PubMed ID: 26579854
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Experience with ustekinumab for the treatment of moderate to severe hidradenitis suppurativa.
    Gulliver WP; Jemec GB; Baker KA
    J Eur Acad Dermatol Venereol; 2012 Jul; 26(7):911-4. PubMed ID: 21605174
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Paradoxical Hidradenitis Suppurativa during Biologic Therapy, an Emerging Challenge: A Systematic Review.
    Ruggiero A; Martora F; Picone V; Marano L; Fabbrocini G; Marasca C
    Biomedicines; 2022 Feb; 10(2):. PubMed ID: 35203664
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Failure of Anakinra in a Case of Severe Hidradenitis Suppurativa.
    Russo V; Alikhan A
    J Drugs Dermatol; 2016 Jun; 15(6):772-4. PubMed ID: 27272089
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Decreased Serum Level of Interleukin-22 Correlates with Hepcidin in Patients with Hidradenitis Suppurativa.
    Ponikowska M; Matusiak Ł; Kasztura M; Jankowska E; Szepietowski JC
    Acta Derm Venereol; 2021 Sep; 101(9):adv00558. PubMed ID: 34515804
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.